Sapient Capital LLC Acquires New Shares in McKesson Corporation $MCK

Key Points

• Sapient Capital acquired 1,076 McKesson shares worth approximately $919,000 during the third quarter, while institutional investors collectively own 85.07% of the company.
• McKesson’s latest quarterly results exceeded expectations, with earnings of $9.93 per share and revenue of $105.38 billion, up 7.7% year over year. The company also raised its quarterly dividend to $0.94 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $973.19, though the stock’s elevated valuation and planned $1.4 billion investment in Option Care create execution risks.

Sapient Capital LLC acquired a new stake in shares of McKesson Corporation (NYSE:MCK - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,076 shares of the company's stock, valued at approximately $919,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CoreCap Advisors LLC grew its position in McKesson by 15.3% in the 3rd quarter. CoreCap Advisors LLC now owns 423 shares of the company's stock worth $361,000 after purchasing an additional 56 shares during the period. Apella Capital LLC raised its stake in McKesson by 11.1% during the 3rd quarter. Apella Capital LLC now owns 680 shares of the company's stock valued at $619,000 after buying an additional 68 shares during the last quarter. Everhart Financial Group Inc. lifted its holdings in shares of McKesson by 2.6% during the 3rd quarter. Everhart Financial Group Inc. now owns 2,028 shares of the company's stock valued at $1,732,000 after buying an additional 52 shares during the period. Avidian Wealth Enterprises LLC lifted its holdings in shares of McKesson by 70.5% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 747 shares of the company's stock valued at $638,000 after buying an additional 309 shares during the period. Finally, Valeo Financial Advisors LLC boosted its stake in shares of McKesson by 4.8% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,216 shares of the company's stock worth $1,039,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company's stock.

Insiders Place Their Bets

In other news, Director Bradley E. Lerman sold 301 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer owned 521 shares of the company's stock, valued at $464,445.45. This represents a 17.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.06% of the company's stock.

McKesson Trading Up 2.2%

NYSE MCK opened at $930.64 on Friday. McKesson Corporation has a 12 month low of $723.68 and a 12 month high of $999.00. The stock has a market cap of $108.50 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 1.91 and a beta of 0.30. The company's 50 day moving average is $883.59 and its two-hundred day moving average is $833.03.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping analysts' consensus estimates of $9.56 by $0.37. The business had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company's revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Sell-side analysts forecast that McKesson Corporation will post 44.73 EPS for the current year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Tuesday, September 1st were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, September 1st. This represents a $3.76 annualized dividend and a yield of 0.4%. This is an increase from McKesson's previous quarterly dividend of $0.82. McKesson's payout ratio is currently 10.06%.

Analyst Upgrades and Downgrades

Several analysts recently commented on MCK shares. Wall Street Zen lowered McKesson from a "buy" rating to a "hold" rating in a report on Saturday, June 27th. Weiss Ratings upgraded McKesson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, September 4th. Citigroup boosted their price target on McKesson from $945.00 to $1,000.00 and gave the company a "buy" rating in a research note on Friday, July 24th. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada reissued a "sector perform" rating and issued a $845.00 price objective on shares of McKesson in a report on Monday, September 14th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $973.19.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Option Care acquisition expands McKesson’s healthcare platform. McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health in a transaction valued at approximately $5.8 billion. McKesson plans to invest about $1.4 billion for a 49% stake, giving it exposure to the growing home- and outpatient-infusion market. The deal is expected to benefit from the shift of complex treatments away from hospitals, although integration and execution will be important. CD&R and McKesson ink $5.8bn take-private deal for Option Care Health
• Positive Sentiment: Leerink Partners raised its price target and maintained an outperform rating. The firm increased its target to $1,070 from $1,030, implying roughly 15% upside from the referenced price. The revision adds to the broader analyst support for McKesson, which carries a consensus “Moderate Buy” recommendation. Leerink Partners Adjusts Price Target on McKesson to $1,070
• Positive Sentiment: Growth and earnings trends remain favorable. Zacks highlighted McKesson’s above-average financial growth and positive growth-stock characteristics. In its latest reported quarter, revenue rose 7.7% year over year and adjusted earnings exceeded analysts’ expectations, reinforcing confidence in the company’s outlook. Here’s Why McKesson Is a Strong Growth Stock
• Neutral Sentiment: Analyst recommendations are supportive but may already be reflected in the valuation. Multiple reports point to bullish brokerage views, while comparisons with other medical stocks show McKesson’s strong year-to-date performance. Investors may therefore focus more heavily on whether future earnings and the Option Care transaction justify the stock’s elevated valuation. Is It Worth Investing in McKesson Based on Wall Street’s Bullish Views?
• Negative Sentiment: The Option Care deal creates capital and execution risks. McKesson’s planned $1.4 billion investment represents a substantial commitment, and the transaction could pressure near-term returns if expected synergies or growth in home infusion take longer to materialize. The stock also remains near its 12-month high, leaving less room for disappointment.

McKesson Profile

McKesson Corporation NYSE: MCK is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson's principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.